Steatosis induced CCL5 contributes to early-stage liver fibrosis in nonalcoholic fatty liver disease progress

Translational Research

Volumn 180, Issue , 2017, Pages 103-117.e4

  Li, Bing Hang ^a   He, Fang Ping ^b   Yang, Xin ^c   Chen, Yuan Wen ^a   Fan, Jian Gao ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b XINJIANG MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF ALABAMA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; BIOLOGICAL MARKER; CASPASE 3; CCAAT ENHANCER BINDING PROTEIN BETA; CHEMOKINE RECEPTOR CCR5; COLLAGEN TYPE 1; COLLAGEN TYPE 1 ALPHA 1; GELATINASE A; HYDROXYPROLINE; INTERLEUKIN 1BETA; MESSENGER RNA; MYC PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN C MYB; RANTES; REGULATORY FACTOR X1; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR ETS 2; TRANSCRIPTION FACTOR GATA 1; TRANSCRIPTION FACTOR PAX5; TRANSCRIPTION FACTOR PEA3; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR YY1; TRANSFORMING GROWTH FACTOR BETA1; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UPSTREAM STIMULATORY FACTOR 1; X BOX BINDING PROTEIN 1; TRANSCRIPTION FACTOR;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CLINICAL ARTICLE; COLLAGEN SYNTHESIS; CONDITIONED MEDIUM; CONTROLLED STUDY; DISEASE COURSE; GENETIC TRANSCRIPTION; HEPATIC STELLATE CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; LIPID DIET; LIVER CELL; LIVER FIBROSIS; LIVER HEMANGIOMA; MALE; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; STEATOSIS; UPREGULATION; ANIMAL; BLOOD; CASE CONTROL STUDY; COMPLICATION; FEMALE; GENE SILENCING; GENETICS; LIVER; LIVER CIRRHOSIS; METABOLISM; PATHOLOGY; PROMOTER REGION; STAINING; WISTAR RAT;

ADULT; ANIMALS; CASE-CONTROL STUDIES; CHEMOKINE CCL5; DISEASE PROGRESSION; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PROMOTER REGIONS, GENETIC; RATS, WISTAR; RNA, MESSENGER; STAINING AND LABELING; TRANSCRIPTION FACTORS;

EID: 84995770325     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2016.08.006     Document Type: Article

References (63)

1. 1 Li, Z., Xue, J., Chen, P., Chen, L., Yan, S., Liu, L., Prevalence of nonalcoholic fatty liver disease in mainland of China: a meta-analysis of published studies. J Gastroenterol Hepatol 29 (2014), 42–51.
2. 2 Browning, J.D., Szczepaniak, L.S., Dobbins, R., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40 (2004), 1387–1395.
3. 3 Papatheodoridis, G.V., Goulis, J., Christodoulou, D., et al. High prevalence of elevated liver enzymes in blood donors: associations with male gender and central adiposity. Eur J Gastroenterol Hepatol 19 (2007), 281–287.
4. 4 Bugianesi, E., Leone, N., Vanni, E., et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 123 (2002), 134–140.
5. 5 Barshop, N.J., Sirlin, C.B., Schwimmer, J.B., Lavine, J.E., Review article: epidemiology, pathogenesis and potential treatments of paediatric non-alcoholic fatty liver disease. Aliment Pharmacol Ther 28 (2008), 13–24.
6. 6 Farrell, G.C., van Rooyen, D., Gan, L., Chitturi, S., Nash is an inflammatory Disorder: Pathogenic, Prognostic and therapeutic implications. Gut Liver 6 (2012), 149–171.
7. 7 Adams, L.A., Knuiman, M.W., Divitini, M.L., Olynyk, J.K., Body mass index is a stronger predictor of alanine aminotransaminase levels than alcohol consumption. J Gastroenterol Hepatol 23 (2008), 1089–1093.
8. 8 Tsochatzis, E., Papatheodoridis, G.V., Manesis, E.K., Kafiri, G., Tiniakos, D.G., Archimandritis, A.J., Metabolic syndrome is associated with severe fibrosis in chronic viral hepatitis and non-alcoholic steatohepatitis. Aliment Pharmacol Ther 27 (2008), 80–89.
9. 9 Tsochatzis, E.A., Manolakopoulos, S., Papatheodoridis, G.V., Archimandritis, A.J., Insulin resistance and metabolic syndrome in chronic liver diseases: old entities with new implications. Scand J Gastroenterol 44 (2009), 6–14.
10. 10 Calamita, G., Portincasa, P., Present and future therapeutic strategies in non-alcoholic fatty liver disease. Expert Opin Ther Targets 11 (2007), 1231–1249.
11. 11 Carter-Kent, C., Zein, N.N., Feldstein, A.E., Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment. Am J Gastroenterol 103 (2008), 1036–1042.
12. 12 Liu, Q., Bengmark, S., Qu, S., The role of hepatic fat accumulation in pathogenesis of non-alcoholic fatty liver disease (NAFLD). Lipids Health Dis, 9, 2010, 42.
13. 13 Braunersreuther, V., Viviani, G.L., Mach, F., Montecucco, F., Role of cytokines and chemokines in non-alcoholic fatty liver disease. World J Gastroenterol 18 (2012), 727–735.
14. 14 Day, C.P., James, O.F., Steatohepatitis: a tale of two “hits”?. Gastroenterology 114 (1998), 842–845.
15. 15 Jiao, J., Friedman, S.L., Aloman, C., Hepatic fibrosis. Curr Opin Gastroenterol 25 (2009), 223–229.
16. 16 Schall, T.J., Jongstra, J., Dyer, B.J., et al. A human T cell-specific molecule is a member of a new gene family. J Immunol 141 (1988), 1018–1025.
17. 17 Nischalke, H.D., Nattermann, J., Fischer, H.P., Sauerbruch, T., Spengler, U., Dumoulin, F.L., Semiquantitative analysis of intrahepatic CC-chemokine mRNas in chronic hepatitis C. Mediators Inflamm 13 (2004), 357–359.
18. 18 Seki, E., De Minicis, S., Gwak, G.Y., et al. CCR1 and CCR5 promote hepatic fibrosis in mice. J Clin Invest 119 (2009), 1858–1870.
19. 19 Berres, M.L., Koenen, R.R., Rueland, A., et al. Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice. The J Clin Invest 120 (2010), 4129–4140.
20. 20 Wu, H., Ghosh, S., Perrard, X.D., et al. T-cell accumulation and regulated on activation, normal T cell expressed and secreted upregulation in adipose tissue in obesity. Circulation 115 (2007), 1029–1038.
21. 21 Kirovski, G., Gabele, E., Dorn, C., et al. Hepatic steatosis causes induction of the chemokine RANTES in the absence of significant hepatic inflammation. Int J Clin Exp Pathol 3 (2010), 675–680.
22. 22 Chalasani, N., Younossi, Z., Lavine, J.E., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological association, American association for the study of liver diseases, and American College of Gastroenterology. Gastroenterology 142 (2012), 1592–1609.
23. 23 Devi, A.J., Ravindran, R., Sankar, M., Rajkumar, J., Effect of ambrex (a herbal formulation) on oxidative stress in hyperlipidemic rats and differentiation of 3T3-L1 preadipocytes. Pharmacogn Mag 10 (2014), 165–171.
24. 24 Schwabe, R.F., Schnabl, B., Kweon, Y.O., Brenner, D.A., CD40 activates NF-kappa B and c-Jun N-terminal kinase and enhances chemokine secretion on activated human hepatic stellate cells. J Immunol 166 (2001), 6812–6819.
25. 25 Mederacke, I., Dapito, D.H., Affo, S., Uchinami, H., Schwabe, R.F., High-yield and high-purity isolation of hepatic stellate cells from normal and fibrotic mouse livers. Nat Protoc 10 (2015), 305–315.
26. 26 He, X., Pu, G., Tang, R., Zhang, D., Pan, W., Activation of nuclear factor kappa B in the hepatic stellate cells of mice with schistosomiasis japonica. PLoS One, 9, 2014, e104323.
27. 27 Schwabe, R.F., Bataller, R., Brenner, D.A., Human hepatic stellate cells express CCR5 and RANTES to induce proliferation and migration. Am J Physiol Gastrointest Liver Physiol 285 (2003), G949–G958.
28. 28 Chagraoui, J., Lepage-Noll, A., Anjo, A., Uzan, G., Charbord, P., Fetal liver stroma consists of cells in epithelial-to-mesenchymal transition. Blood 101 (2003), 2973–2982.
29. 29 Ahsan, M.S., Maruyama, S., Cheng, J., et al. Acetic acid treatment for wrinkle-free oral mucosal epithelia in paraffin section preparation. Microsc Res Tech 74 (2011), 264–268.
30. 30 Zhang, H., Li, Y., Peng, T., et al. Localization of enteroviral antigen in myocardium and other tissues from patients with heart muscle disease by an improved immunohistochemical technique. J Histochem Cytochem 48 (2000), 579–584.
31. 31 Zhang, Y., Xu, N., Xu, J., et al. E2F1 is a novel fibrogenic gene that regulates cholestatic liver fibrosis through the Egr-1/SHP/EID1 network. Hepatology 60 (2014), 919–930.
32. 32 Loizou, S., McCrea, J.D., Rudge, A.C., Reynolds, R., Boyle, C.C., Harris, E.N., Measurement of anti-cardiolipin antibodies by an enzyme-linked immunosorbent assay (ELISA): standardization and quantitation of results. Clin Exp Immunol 62 (1985), 738–745.
33. 33 Liu, H., Lu, J., Hua, Y., et al. Targeting heat-shock protein 90 with ganetespib for molecularly targeted therapy of gastric cancer. Cell Death Dis, 6, 2015, e1595.
34. 34 Sukhanova, A., Gorin, A., Serebriiskii, I.G., et al. Targeting C4-demethylating genes in the cholesterol pathway sensitizes cancer cells to EGF receptor inhibitors via increased EGF receptor degradation. Cancer Discov 3 (2013), 96–111.
35. 35 Tu, Z., Aird, K.M., Bitler, B.G., et al. Oncogenic RAS regulates BRIP1 expression to induce dissociation of BRCA1 from chromatin, inhibit DNA repair, and promote senescence. Dev Cell 21 (2011), 1077–1091.
36. 36 Youdim, K.A., Tyman, C.A., Jones, B.C., Hyland, R., Induction of cytochrome P450: assessment in an immortalized human hepatocyte cell line (Fa2N4) using a novel higher throughput cocktail assay. Drug Metab Dispos 35 (2007), 275–282.
37. 37 Egnatchik, R.A., Leamy, A.K., Noguchi, Y., Shiota, M., Young, J.D., Palmitate-induced activation of mitochondrial metabolism promotes oxidative stress and apoptosis in H4IIEC3 rat hepatocytes. Metab Clin Exp 63 (2014), 283–295.
38. 38 Luo, Y., Rana, P., Will, Y., Palmitate increases the susceptibility of cells to drug-induced toxicity: an in vitro method to identify drugs with potential contraindications in patients with metabolic disease. Toxicol Sci 129 (2012), 346–362.
39. 39 Liu, G., Hu, Y., Xiao, J., et al. (99m)Tc-labelled anti-CD11b SPECT/CT imaging allows detection of plaque destabilization tightly linked to inflammation. Sci Rep, 6, 2016, 20900.
40. 40 Jia, L., Song, N., Yang, G., et al. Effects of Tanshinone IIA on the modulation of miR33a and the SREBP2/Pcsk9 signaling pathway in hyperlipidemic rats. Mol Med Rep 13 (2016), 4627–4635.
41. 41 Muraoka, R.S., Dumont, N., Ritter, C.A., et al. Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest 109 (2002), 1551–1559.
42. 42 Cheng, C., Haasdijk, R.A., Tempel, D., et al. PDGF-induced migration of vascular smooth muscle cells is inhibited by heme oxygenase-1 via VEGFR2 upregulation and subsequent assembly of inactive VEGFR2/PDGFRbeta heterodimers. Arterioscler Thromb Vasc Biol 32 (2012), 1289–1298.
43. 43 Cairns, J.A., Walls, A.F., Mast cell tryptase stimulates the synthesis of type I collagen in human lung fibroblasts. J Clin Invest 99 (1997), 1313–1321.
44. 44 Abe, M., Kurosawa, M., Ishikawa, O., Miyachi, Y., Kido, H., Mast cell tryptase stimulates both human dermal fibroblast proliferation and type I collagen production. Clin Exp Allergy 28 (1998), 1509–1517.
45. 45 Pan, D., Coen, D.M., Net -1 frameshifting on a noncanonical sequence in a herpes simplex virus drug-resistant mutant is stimulated by nonstop mRNA. Proc Natl Acad Sci U S A 109 (2012), 14852–14857.
46. 46 Luo, Y., Hara, T., Ishido, Y., et al. Rapid preparation of high-purity nuclear proteins from a small number of cultured cells for use in electrophoretic mobility shift assays. BMC Immunol, 15, 2014, 62.
47. 47 Tu, Z., Zhuang, X., Yao, Y.G., Zhang, R., BRG1 is required for formation of senescence-associated heterochromatin foci induced by oncogenic RAS or BRCA1 loss. Mol Cell Biol 33 (2013), 1819–1829.
48. 48 Robinson, S.C., Scott, K.A., Wilson, J.L., Thompson, R.G., Proudfoot, A.E., Balkwill, F.R., A chemokine receptor antagonist inhibits experimental breast tumor growth. Cancer Res 63 (2003), 8360–8365.
49. 49 Pham, K., Luo, D., Liu, C., Harrison, J.K., CCL5, CCR1 and CCR5 in murine glioblastoma: immune cell infiltration and survival rates are not dependent on individual expression of either CCR1 or CCR5. J Neuroimmunol 246 (2012), 10–17.
50. 50 Wu, X., Zhang, L., Gurley, E., et al. Prevention of free fatty acid-induced hepatic lipotoxicity by 18beta-glycyrrhetinic acid through lysosomal and mitochondrial pathways. Hepatology 47 (2008), 1905–1915.
51. 51 Geng, T., Hu, W., Broadwater, M.H., et al. Fatty acids differentially regulate insulin resistance through endoplasm reticulum stress-mediated induction of tribbles homologue 3: a potential link between dietary fat composition and the pathophysiological outcomes of obesity. Diabetologia 56 (2013), 2078–2087.
52. 52 Guo, J., Friedman, S.L., Hepatic fibrogenesis. Semin Liver Dis 27 (2007), 413–426.
53. 53 Zheng, W.D., Zhang, L.J., Shi, M.N., et al. Expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 in hepatic stellate cells during rat hepatic fibrosis and its intervention by IL-10. World J Gastroenterol 11 (2005), 1753–1758.
54. 54 Shi, Y.F., Fong, C.C., Zhang, Q., et al. Hypoxia induces the activation of human hepatic stellate cells LX-2 through TGF-beta signaling pathway. FEBS Lett 581 (2007), 203–210.
55. 55 Liang, F.F., Liu, C.P., Li, L.X., et al. Activated effects of parathyroid hormone-related protein on human hepatic stellate cells. PLoS One, 8, 2013, e76517.
56. 56 Bataller, R., Brenner, D.A., Liver fibrosis. J Clin Invest 115 (2005), 209–218.
57. 57 van der Krieken, S.E., Popeijus, H.E., Mensink, R.P., Plat, J., CCAAT/enhancer binding protein beta in relation to ER stress, inflammation, and metabolic disturbances. Biomed Res Int, 2015, 2015, 324815.
58. 58 Natsuka, S., Akira, S., Nishio, Y., et al. Macrophage differentiation-specific expression of NF-IL6, a transcription factor for interleukin-6. Blood 79 (1992), 460–466.
59. 59 Greenwel, P., Tanaka, S., Penkov, D., et al. Tumor necrosis factor alpha inhibits type I collagen synthesis through repressive CCAAT/enhancer-binding proteins. Mol Cell Biol 20 (2000), 912–918.
60. 60 Fessele, S., Boehlk, S., Mojaat, A., et al. Molecular and in silico characterization of a promoter module and C/EBP element that mediate LPS-induced RANTES/CCL5 expression in monocytic cells. FASEB J 15 (2001), 577–579.
61. 61 Perez-Martinez, L., Perez-Matute, P., Aguilera-Lizarraga, J., et al. Maraviroc, a CCR5 antagonist, ameliorates the development of hepatic steatosis in a mouse model of non-alcoholic fatty liver disease (NAFLD). J Antimicrob Chemother 69 (2014), 1903–1910.
62. 62 Honczarenko, M., Le, Y., Glodek, A.M., et al. CCR5-binding chemokines modulate CXCL12 (SDF-1)-induced responses of progenitor B cells in human bone marrow through heterologous desensitization of the CXCR4 chemokine receptor. Blood 100 (2002), 2321–2329.
63. 63 Klibanov, O.M., Williams, S.H., Iler, C.A., Cenicriviroc, an orally active CCR5 antagonist for the potential treatment of HIV infection. Curr Opin Investig Drugs 11 (2010), 940–950.